In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

Breast cancer (BRCA) remains the most common malignant cancer in women worldwide. Although a range of treatments exists, ...

Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence ...

Scientists have created a new light-based cancer therapy that targets tumors precisely without harming healthy cells.

As cancer cases continue to rise and combination therapies gain prominence, the global cytotoxic drugs market is set for ...

Another treatment option available for certain types of cancer is the use of targeted radionuclide therapy, which is based ... unlike chemotherapy, these radioactive substances specifically target ...

Chemotherapy fights lung cancer by targeting fast-growing cells. This treatment can cause fatigue, nausea, hair loss, and ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline trials through accelerated approval pathways, ...